Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VBI 2601

Next Previous
X
Search
Drug Profile

VBI 2601

Alternative Names: BRII-179; VBI-2601

Latest Information Update: 24 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VBI Vaccines
  • Developer Brii Biosciences; VBI Vaccines
  • Class Antivirals; Hepatitis B vaccines; Immunotherapies; Protein vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 21 Oct 2024 Brii Biosciences plans a phase II ENHANCE trial for Hepatitis B (Combination therapy) in China (IM), in November 2024 (NCT06650852)
  • 09 Jul 2024 Brii Biosciences Limited plans a phase II ENRICH trial for Hepatitis-B (Combination therapy, Adjunctive treatment) in China (IM, Injection)(NCT06491563)
  • 07 Jun 2024 Efficacy and adverse evets data from phase-II trial in Hepatitis-B released by Brii Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top